Octreoteva Long Acting (Octreotide Acetate)

Octreotide Acetate, the active ingredient in Octreoteva Long Acting, is a peptide hormone/somatostatin analog presented as a long‑acting injectable formulation for subcutaneous use. It is used to control hormone‑secreting tumors and related conditions.

GNH USA supplies Octreoteva Long Acting as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octreoteva Long Acting is a somatostatin analog indicated for conditions driven by excess hormone secretion.

Acromegaly: reduces growth hormone levels and controls disease activity. Carcinoid syndrome: decreases serotonin release and alleviates flushing and diarrhea. VIPoma: suppresses vasoactive intestinal peptide secretion, reducing watery diarrhoea and electrolyte loss.

Octreoteva Long Acting may cause a range of adverse reactions.

Common Side Effects: - Abdominal pain or discomfort - Nausea and vomiting - Diarrhoea or constipation - Injection‑site erythema or induration - Gallstone formation - Hyperglycaemia or altered glucose tolerance

Serious or Rare Side Effects: - Severe bradycardia or cardiac arrhythmias - Acute pancreatitis - Anaphylactic or severe allergic reactions - Hepatic dysfunction or jaundice - Hypothyroidism or adrenal insufficiency - Thromboembolic events

Before initiating therapy, consider the following precautions.

Monitor blood glucose: adjust antidiabetic therapy as needed. Assess gallbladder status: patients with gallstones may require monitoring. Evaluate cardiac function: caution in patients with known conduction abnormalities. Dose adjustment in hepatic or renal impairment: consider reduced dosing. Avoid in known hypersensitivity to octreotide or formulation components. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreoteva Long Acting can interact with several medicines.

Major Interactions (Avoid): - Cyclosporine: may increase octreotide plasma concentrations. - Somatostatin analog combinations: additive hormonal suppression. - Quinidine: risk of QT prolongation may be heightened.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy due to decreased enterohepatic recirculation. - Antidiabetic agents: altered glucose control may require dose adjustment. - Antiplatelet or anticoagulant drugs: potential for increased bleeding risk.